LSTA
Lisata Therapeutics, Inc. NASDAQ Listed Mar 1, 1999$3.48
+0.29%
vs $3.47
Mkt Cap $31.7M
52w Low $1.81
51.2% of range
52w High $5.07
50d MA $3.40
200d MA $3.19
P/E (TTM)
—
EV/EBITDA
—
P/B
2.1x
Debt/Equity
0.0x
ROE
-111.7%
P/FCF
-1.9x
RSI (14)
44.30
ATR (14)
$0.15
Beta
1.11
50d MA
$3.40
200d MA
$3.19
Avg Volume
158.0K
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
110 Allen Road · Basking Ridge, NJ 07920 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.51 | -0.33 | +35.3% | 5.03 | -0.4% | +0.0% | +0.2% | -0.2% | -0.4% | +0.2% | — |
| Nov 6, 2025 | AMC | -0.54 | -0.49 | +9.3% | 2.35 | -9.4% | -12.3% | +1.9% | +0.0% | +2.9% | -4.2% | — |
| Aug 7, 2025 | AMC | -0.65 | -0.54 | +16.9% | 2.80 | -5.0% | -7.1% | +6.5% | -5.4% | +1.5% | -3.8% | — |
| May 8, 2025 | AMC | -0.53 | -0.55 | -3.8% | 2.37 | +0.8% | -11.4% | +5.7% | +2.7% | -4.4% | +10.1% | — |
| Feb 27, 2025 | AMC | -0.76 | -0.55 | +27.6% | 2.40 | -3.8% | -0.8% | -9.7% | +0.0% | +10.2% | -1.3% | — |
| Nov 12, 2024 | AMC | -0.75 | -0.59 | +21.3% | 2.91 | -1.4% | -4.1% | +0.7% | +1.4% | -4.6% | +1.1% | — |
| Aug 12, 2024 | AMC | -0.75 | -0.61 | +18.7% | 2.93 | +2.4% | +0.3% | -1.0% | -0.7% | -1.4% | +3.9% | — |
| May 9, 2024 | AMC | -0.73 | -0.65 | +11.0% | 2.91 | -0.3% | +1.4% | -5.8% | +6.5% | -4.1% | -0.7% | — |
| Feb 29, 2024 | AMC | -0.86 | -0.66 | +23.3% | 2.93 | +0.3% | +5.8% | +4.5% | -3.7% | -1.0% | -1.0% | — |
| Nov 2, 2023 | AMC | -0.93 | -0.65 | +30.1% | 2.18 | +2.2% | +8.3% | -3.4% | -1.8% | +0.0% | -5.8% | — |
| Aug 14, 2023 | AMC | -0.70 | -0.50 | +28.6% | 2.70 | +0.0% | +0.0% | -0.7% | +0.9% | +0.2% | +0.4% | — |
| May 9, 2023 | AMC | -0.81 | -0.77 | +4.9% | 3.27 | -4.9% | -0.5% | +0.7% | +0.7% | +2.7% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 21 | Brookline Capital | Downgrade | Buy → Hold | — | $2.16 | $3.99 | +84.7% | +86.6% | +0.7% | +1.2% | -1.0% | +12.3% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.40 | $2.38 | -0.8% | +2.9% | +4.9% | -2.3% | -0.8% | -0.4% |
| Jul 15 | Brookline Capital | Maintains | Buy → Buy | — | $2.63 | $2.53 | -3.8% | +2.7% | -4.8% | -6.2% | +5.0% | +2.0% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.79 | -1.1% | -7.1% | +4.2% | -5.5% | +1.2% | +1.5% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.93 | $2.92 | -0.3% | -3.1% | +1.4% | +0.0% | -1.4% | -0.7% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.10 | $3.05 | -1.6% | -4.8% | +2.4% | +5.3% | -2.5% | -4.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.93 | $3.00 | +2.4% | +0.3% | -1.0% | -0.7% | -1.4% | +3.9% |
| Jul 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $3.63 | +2.3% | +0.0% | -0.3% | -1.1% | -2.3% | +0.3% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.36 | $3.41 | +1.5% | +1.5% | +2.1% | +5.7% | -0.8% | +1.4% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.47 | $3.51 | +1.2% | +3.7% | -4.4% | -4.1% | +2.1% | +4.7% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.86 | +1.4% | +6.4% | +3.7% | +1.9% | -6.6% | -2.7% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $2.74 | +3.0% | -0.4% | +3.8% | -0.7% | +4.4% | +2.8% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $2.75 | -2.8% | -6.0% | -0.4% | +3.8% | -0.7% | +4.4% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.93 | $2.94 | +0.3% | +5.8% | +4.5% | -3.7% | -1.0% | -1.0% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $3.05 | +8.9% | +7.9% | -2.3% | +4.1% | +0.3% | -2.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.70 | $2.70 | +0.0% | +0.0% | -0.7% | +0.9% | +0.2% | +0.4% |
| May 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.08 | -0.7% | -5.1% | -0.5% | -0.5% | +6.2% | +3.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.02 | -5.0% | +2.0% | +0.2% | -2.2% | -3.0% | -0.2% |
| Oct 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.41 | +5.5% | -1.2% | +0.7% | -0.7% | -3.6% | +0.5% |
No insider trades available.
SC TO-T
!!! Very High
Lisata Therapeutics, Inc. -- Tender Offer
Lisata Therapeutics' tender offer at $4.00 per share represents a potential going-private transaction, allowing shareholders to exit at a fixed price while the company evaluates strategic alternatives.
Jun 10
8-K · 1.01
!!! Very High
Lisata Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Jun 9
8-K · 8.01
!! High
Lisata Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Lisata Therapeutics amended its merger agreement with Kuva Labs on May 29, 2026, modifying terms of the previously announced March acquisition deal.
Jun 1
8-K · 1.01
!!! Very High
Lisata Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Lisata Therapeutics amended its merger agreement with Kuva Labs, with Kuva agreeing to cover additional company expenses, modifying terms of the previously announced acquisition deal.
May 4
8-K
Unknown — 8-K Filing
A potential acquisition of Lisata is being contemplated, requiring investors to await formal tender offer documents before evaluating the deal's terms, price, and strategic implications for shareholders.
Apr 15
8-K
Unknown — 8-K Filing
LSTA is undergoing a tender offer acquisition process, meaning shareholders should expect formal SEC filings soon detailing the purchase price and timeline for this transaction.
Apr 3
8-K · 1.01
!!! Very High
Lisata Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Lisata Therapeutics agreed to merge with Kuva Labs Inc., combining the two biotechnology companies into a single entity.
Mar 9
8-K · 1.01
!! High
Lisata Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Lisata Therapeutics extended its binding term sheet with Kuva to March 7, 2026, suggesting ongoing negotiations for a potential partnership or transaction between the two companies.
Feb 27
Institutional (13F) — Top 19
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 271,815 | $1M | New | Mar 2026 |
| 2 | Renaissance Technologies Llc | 131,715 | $660K | Added | Mar 2026 |
| 3 | Rangeley Capital, Llc | 75,000 | $376K | New | Mar 2026 |
| 4 | Citadel Advisors Llc | 22,666 | $114K | New | Mar 2026 |
| 5 | Ground Swell Capital, Llc | 38,987 | $73K | Added | Dec 2025 |
| 6 | Jbf Capital, Inc. | 13,234 | $66K | New | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 11,604 | $58K | New | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 10,353 | $52K | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 10,268 | $51K | — | Mar 2026 |
| 10 | Royal Bank Of Canada | 5,912 | $29K | — | Mar 2026 |
| 11 | Hightower Advisors, Llc | 10,042 | $19K | — | Dec 2025 |
| 12 | Ubs Group Ag | 1,909 | $10K | Added | Mar 2026 |
| 13 | Founders Capital Management | 1,667 | $8K | — | Mar 2026 |
| 14 | Connective Capital Management, Llc | 1,016 | $5K | — | Mar 2026 |
| 15 | Morgan Stanley | 150 | $280 | Reduced | Dec 2025 |
| 16 | Virtu Financial Llc | 42,213 | $211 | New | Mar 2026 |
| 17 | Fortitude Family Office, Llc | 1 | $5 | — | Mar 2026 |
| 18 | Citigroup Inc | 1 | $2 | New | Dec 2025 |
| 19 | Fmr Llc | — | — | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 41,218 | $169K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 9,230 | $38K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 4,379 | $18K | Feb 2026 |
| 4 | Dimensional U.S. Equity Market ETF | 3,851 | $18K | Jan 2026 |
| 5 | U.S. Social Core Equity 2 Portfolio | 2,185 | $10K | Jan 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 2,010 | $8K | Feb 2026 |
| 7 | LVIP Dimensional U.S. Core Equity 2 Fund | 100 | $501 | Mar 2026 |
| 8 | Dimensional US Sustainability Core 1 ETF | 100 | $463 | Jan 2026 |
| 9 | Dimensional US Core Equity 1 ETF | 8 | $37 | Jan 2026 |
Valuation
Market Cap
$31.7M
Enterprise Value
$14.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.05x
P/B
2.07x
P/S
177.83x
P/FCF
-1.89x
EV/EBITDA
—
Shares Out
8.7M
Financials (TTM)
Revenue
$170K
Net Income
-$16.4M
EBITDA
-$16.6M
Free Cash Flow
-$16.0M
Op Cash Flow
-$15.9M
EPS Basic
$-1.91
EPS Diluted
$-1.86
EPS Forward
$-0.96
Gross Margin
98.8%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$17.7M
Total Liab.
$3.1M
Total Equity
$14.6M
Cash
$16.0M
LT Debt
$0
Book Value/Sh
$1.68
Debt/Equity
0.00x
Current Ratio
5.76
Quick Ratio
5.76
Returns & Growth
ROE
-111.7%
ROA
-93.5%
ROIC
-117.3%
Rev Growth YoY
-83.0%
EPS Growth YoY
+20.4%
Price Returns
2W
+5.5%
1M
+4.2%
3M
-20.7%
6M
+57.8%
12M
+24.5%
Technicals
52W High
$5.07
52W Low
$1.81
50d MA
$3.40
200d MA
$3.19
RSI (14)
44.30
ATR (14)
$0.15
Beta
1.11
Avg Volume
158K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 7:58pm
· Source: financialmodelingprep.com